Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, announced results for the Second Quarter Fiscal Year (FY) 2012 ended October 31, 2011. Total operating expenses for the period ended October 31, 2011 were $2,149,387 compared to $2,083,863 for the same period in 2010. Net revenue for the six months ended October 31, 2011 was $120,032 compared to total revenue of $32,236 for the same period in fiscal year 2011. This increase was primarily due to grant revenues earned in the current quarter. Product revenue also increased slightly for the six months ended October 31, 2011 compared to the same period in the prior year due to shipments to our distributor in Mexico.

Oxygen Biotherapeutics, Inc. develops medical and cosmetic products that deliver oxygen to tissues in the body.

Read full article at : http://doubleinstocks.com/?p=19797


THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services and 4,000,000 shares of 144 restricted stocks from the company for management fee through end of June for Cleantech Transit, Inc. (CLNO.OB).